color pdf

BIMM118
Phase IV studies:
• Postmarketing Surveillance
– Ongoing monitoring of drug safety under actual conditions of use in
large numbers of patients. (Pharmacovigilance)
– Physician and pharmacist reporting of adverse drug events
– No fixed duration
– Picks up adverse events occurring in less than one in 1000
subjects